cancel
Showing results for 
Search instead for 
Did you mean: 

BLOG: Creation of bone in the lab to design treatments for metastatic disease

Chris_McNamara
Community Manager
Community Manager
0 0 29

Creation of bone in the lab to design treatments for metastatic disease

As mentioned in previous research blogs, advanced prostate cancer is treated with androgen deprivation therapy to suppress the levels of testosterone and slow down tumour growth. With time the cancer develops mechanisms to outsmart this therapy (castrate resistant prostate cancer [CRPC]). One of the results is the spread of cancer to bone (found in up to 90% of patients with metastatic CRPC[mCRPC]). These deposits result in pain and pathological fractures. Very few treatments have shown survival benefit. Recent data suggest that targeting the tumour cells and the bone microenvironment improves survival. The role of the tumour microenvironment as a key modulator of tumour cell response to therapy is still unclear. Since bone metastasis is mostly always present in the castration-resistant phase it is important to determine the effects of standard androgen deprivation therapy (ADT) in the bone tumour microenvironment. Cancer cells induce stem cell osteogenic differentiation and osteoblast activation (the processes that are responsible for laying down bone). While some mechanisms have been proposed, the factors involved in the cross-talk between cancer cells and the bone microenvironment still need to be identified. Understanding the molecular actors involved in the adaptation of the bone tumor microenvironment to ADT is crucial for the identification of molecular drug targets for mCRPC. The main challenge has been adequately modelling the disease process in the lab. Previously bone modelling has been on animal tissue which has its limitations.

Dr Nathalie Bock and her team from the Queensland University of Technology have developed and validated a highly reproducible microtissue-engineered human construct in the lab that comprises osteocytic and osteoblastic cells (the cells responsible for the breakdown and formation of bone), with relevant protein expression and mineral content. The mature mineralized engineered tissue are cultured for up to 12 weeks. They then add metastatic prostate cancer cells to the mineralized microtissue. This model reproduces some of the cellular alterations seen in the human body under androgen deprivation therapy, followed by three-dimensional morphometric and functional characterization at the cellular level. They are also able to demonstrate the interactions between the tumor and the bone microenvironment. They looked at the outcomes in two different drug classes: bicalutamide and enzalutamide combining 4D live microscopy, cell morphometry, and gene and protein analysis.

The researchers found a strong correlation between the architecture and function of their model compared to bone in a person with metastatic prostate cancer. One of the mechanisms for the cancer to outsmart drug therapy is by altering the testosterone receptors in cells where the drugs take their effect. In the bone model this adaptive response by the tumour cells was confirmed. The cancer is able to resemble a resident bone cell (osteomimicry) and take over its normal functioning. They are also able to evade the effects of the ADT and continue to grow and invade the bone further. Bock and her team were also able to demonstrate that in some cancers, resistance to treatment might already exist before treatment even begins, suggesting that alternative modes of treatment (i.e that don’t target testosterone receptors) may need to be offered upfront. Another interesting finding was that the routine PSA blood test did not always reflect what was happening at the cellular level in the bone. If PSA could be sampled from bone with cancer metastases it could prove to yield a higher value. In terms of the two drug classes it was shown that there may be worse outcomes with bicalutamide yet stronger genomic dysregulation using enzalutamide in this microenvironment.

This breakthrough work by Dr Bock and her team will be paramount in offering preclinical diagnostic testing at the initial visit to the urologist before surgery or radiation occur. Often the journey for someone with mCRPC is long and complex, trialling and failing multiple treatment options along the way. With the rise in personalised and tailored treatment approaches, models like these may aid in diagnosing who may developed mCRPC, why they develop it and the design of specific treatment. In this way we can outsmart the cancer and beat it at its own game.

 

Reference article

Bock, T. Kryza, A. Shokoohmand, J. Röhl, A. Ravichandran, M.-L. Wille, C. C. Nelson, D. W. Hutmacher, J. A. Clements, In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer. Sci. Adv. 7, eabg2564 (2021).

 

Chris_McNamara_0-1622520551637.jpeg

 

 

 

 

 

 About the Author

Kalli Spencer

MBBCh, FC Urol (SA), MMed (Urol), Dip.Couns (AIPC)

Kalli is an internationally renowned Urological Surgeon, specialising in oncology and robotic surgery. He trained and worked in South Africa, before relocating to Australia where he has worked at Macquarie University Hospital and Westmead Hospital. His passion for what he does extends beyond the operating room, through public health advocacy, education and community awareness of men’s health, cancer and sexuality.

Kalli has been involved with the Prostate Cancer Foundation of Australia for many years, advocating for improved cancer care and facilitating community prostate cancer support groups.

 

House Rules

To help keep this community a welcoming, supportive and caring place we have put together a small list of dos and don'ts for you to think about when posting on our forum, research blog or video gallery. For further information please see our  terms and conditions.

Adhere to PCFA’s five core values of Integrity, Optimism, Compassion, Respect and Commitment.

Our online forum is for you to share experiences with others and does not contain specific medical, counselling or legal advice.  If you require professional advice specific to your individual circumstances we encourage you to see a medical professional, legal professional or counsellor.

No commercial or promotional activity. While members may share information about resources they have found helpful, the PCFA Online Community forum should not be used for the promotion of goods and services. This includes commercial entities passing themselves off as individuals and people who frequently post links to external health professionals or other services.

Be kind to each other - many people using the community are going through a difficult time. A few kind words can go a long way. Please welcome new posters – it can be very nerve-wracking to post on the forum for the first time.

If you or someone you know is suffering from mental health issues, such as depression or anxiety, we encourage you to seek assistance and contact Beyond Blue Tel:1300 224 636 or Lifeline Tel:13 11 14

Speak your mind freely, but please be sensitive to the feelings and experiences of others - you might not always agree, but you can agree to disagree in a peaceful manner.

Don't use offensive language -if a user is found to be using offensive language during their conversations the moderators reserve the right to edit the thread, without warning.

Don't use all capital letters in your posts - it's considered ‘shouting' online and it makes posts difficult to read.

Give each other the benefit of the doubt - please remember that it is all too easy for the tone and meaning of posts to be misinterpreted. Think carefully before replying to a discussion. it It is important to remember that things written rather than said can feel much stronger, so please bear this in mind when reading other people's messages.

Please respect the moderators - their job is to keep the forum safe and constructive so that everybody gets to have his or her fair say.

Stay on topic - try to focus on the original topic. In particular, don't change subject in the middle of an existing thread - just start a new thread.

Read what's already on the forum before posting - you may be repeating what others have already said or asked.

We want PCFA's Online Community to be a secure and helpful environment for all of the community. So please remember that by using PCFA's Online Community you are agreeing to follow our terms and conditions.